Pomerantz Law Firm Investigates Neogen Corporation Following FDA Warning Letter and Product Deaths
Pomerantz LLP has launched an investigation into Neogen Corporation (NASDAQ: NEOG) regarding potential securities fraud or unlawful business practices. The probe follows a U.S. Food and Drug Administration (FDA) warning letter issued on September 29, 2026, which linked the company's veterinary wound care product, HYCOAT, to serious infections and at least 20 horse deaths. The FDA noted that this incident represents the largest number of animal deaths ever associated with a quality defect in an FDA-regulated veterinary medical product. Neogen had previously initiated a voluntary recall of the sterile hyaluronate sodium solution in late January 2026. Following the FDA's announcement, Neogen's stock price dropped by 7.22% to close at $12.73 per share.
Tickers: $NEOG
Topics: class action lawsuit FDA warning letter product recall securities fraud investigation veterinary medicine safety
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates Potential Securities Fraud at Integra LifeSciences Holding Corporation (3 articles)